[Featured Stock] GI Innovation Overcomes GLP-1 Obesity Drug Limitations... "Early Stage Technology Transfer Possible"

GI Innovation is showing strong performance. The news that the obesity treatment candidate substance 'GI-213' is being developed as the next-generation main pipeline (product under development) appears to be influencing the stock price.

As of 2:15 PM on the 7th, GI Innovation is trading at 10,780 KRW, up 13.95%.

Minjung Kim, a researcher at DS Investment & Securities, explained, "We have filed a substance patent for GI-213, which promotes fat breakdown, increases energy consumption, and increases muscle mass, resulting in weight loss effects." She added, "Preclinical results showed that although food intake increased, a weight loss of about 36.1% was confirmed for GI-213." She further noted, "We expect that GI-213 can address the yo-yo effect experienced by current drugs like Wegovy and Mounjaro by increasing basal metabolic rate."

Myeongho Jang, the patent inventor and Chief Scientific Officer (CSO) of new drug development and clinical trials, stated, "Global pharmaceutical companies are seeking new treatments that can overcome the limitations of the yo-yo effect occurring after administration of GLP-1 class obesity treatments." He continued, "GI-213, with its differentiated mechanism of increasing basal metabolic rate to reduce weight, is expected to enable early-stage global technology transfer."

GI Innovation explained that while the global obesity treatment market is expected to exceed 100 trillion KRW by 2030, there remain unmet needs such as muscle mass reduction side effects, resistance and slow weight loss from long-term use, and the yo-yo effect after discontinuation.

This content was produced with the assistance of AI translation services.